XML 50 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Details) - Summary Of Changes In SARs Outstanding - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total compensation cost not yet recognized, period for recognition 2 years 8 months 12 days  
Stock appreciation rights    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting period 4 years  
Award expiration period from date of grant 7 years  
Total compensation cost not yet recognized, period for recognition 4 years  
SARs [Roll Forward]    
Outstanding at December 31, 2016 (in shares) 1.3  
Granted (in shares) 0.3  
Exercised (in shares) (0.3)  
Outstanding at June 30, 2017 (in shares) 1.3 1.3
Vested and exercisable at June 30, 2017 (in shares) 0.6  
Aggregate Intrinsic value of outstanding shares $ 61.6  
Aggregate intrinsic value of shares vested and exercisable $ 32.9  
Per Share Weighted- Average Exercise Price [Roll Forward]    
Outstanding at December 31, 2016 (in dollars per share) $ 66.22  
Granted (in dollars per share) 99.07  
Exercised (in dollars per share) 51.25  
Outstanding at June 30, 2017 (in dollars per share) 76.64 $ 66.22
Vested and exercisable at June 30, 2017 (in dollars per share) 64.71  
Per Share Weighted Average Grant Date Fair Value [Roll Forward]    
Outstanding at December 31, 2016 (in dollars per share) 15.77  
Granted (in dollars per share) 22.02  
Exercised (in dollars per share) 14.74  
Outstanding at June 30, 2017 (in dollars per share) 17.36 $ 15.77
Vested and exercisable at June 30, 2017 (in dollars per share) $ 15.60  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Remaining Contractual Term [Abstract]    
Granted 6 years 7 months 6 days  
Outstanding weighted average remaining contractual term 4 years 9 months 26 days 4 years 4 months 24 days
Vested and exercisable at June 30, 2017 3 years 8 months 27 days  
Unvested | Stock appreciation rights    
SARs [Roll Forward]    
Outstanding at June 30, 2017 (in shares) 0.7